TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35106694

Group type: EXPERIMENTAL
Intervention: D‐IUI and D‐IVF treatments in single women (SW)
Number of subjects: 251

Group type: COMPARATOR
Intervention: D‐IUI and D‐IVF treatments in women in lesbian relationships (WLR)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: D‐IUI treatments
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: D‐IVF treatments
Number of subjects: 251
Study: 33607321

Group type: EXPERIMENTAL
Intervention: Quality criteria for randomized controlled trials as listed in author guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Submission software requirements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between top medical journals and other obstetrics and gynecology journals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison among top vs other obstetrics and gynecology journals
Number of subjects: 0
Study: 35708047

Group type: EXPERIMENTAL
Intervention: Exoskeleton exercise (Exo)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No exoskeleton exercise (Nxo)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control (Con)
Number of subjects: 40
Study: 34738828

Group type: EXPERIMENTAL
Intervention: Pure plug-based technique (MANTA, Teleflex)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Primary suture-based technique (ProGlide, Abbott Vascular)
Number of subjects: 516
Study: 33693537

Group type: COMPARATOR
Intervention: Standard-of-care control (PO-10, rifampicin 10 mg/kg/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous rifampicin (IV-20, 20 mg/kg/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-dose oral rifampicin (PO-35, 35 mg/kg/day)
Number of subjects: 61
Study: 32886121

Group type: EXPERIMENTAL
Intervention: Reports containing age-appropriate prevalence data for common imaging findings in individuals without back pain (intervention group)
Number of subjects: 250401

Group type: COMPARATOR
Intervention: Standard lumbar spine imaging reports (control group)
Number of subjects: 250401
Study: 35977831

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic ≤ 125 mm Hg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard blood pressure lowering (systolic 130‐140 mm Hg)
Number of subjects: 82
Study: 34424565

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 126
Study: 35115450

Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 344
Study: 33152333

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine-sulfate (HCQS)
Number of subjects: 0
Study: 33549194

Group type: EXPERIMENTAL
Intervention: Posaconazole (300 mg twice on day 1, followed by 300 mg once a day for days 2–84)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2–84)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 575

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 575
Study: 33101762

Group type: EXPERIMENTAL
Intervention: Viewing the writing process vs. only rating spiral/writing photos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rating each arm individually vs. concurrently
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supine vs. sitting position for heal to shin scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cursive writing vs. script writing
Number of subjects: 0
Study: 36289083

Group type: EXPERIMENTAL
Intervention: Touch Surgery™ (TS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Virtual Reality (VR) trainer
Number of subjects: 40
Study: 34564985

Group type: EXPERIMENTAL
Intervention: NACT combined with laparoscopic cytoreductive surgery
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (cytoreductive surgery alone)
Number of subjects: 116
Study: 32135507

Group type: EXPERIMENTAL
Intervention: Microbial source tracking (MST) assays
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Soil samples
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Stored water samples
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Source water and food surfaces
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Avian target GFD
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Bayesian censored regression and Bayesian logistic regression
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Water storage container characteristics
Number of subjects: 94
Study: 35412627

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis discontinued within 24 hours after surgery (group 24)
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis discontinued 24 to 48 hours after surgery (group 48)
Number of subjects: 1211
Study: 33499139

Group type: EXPERIMENTAL
Intervention: Maqui-citrus beverage with stevia
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Maqui-citrus beverage with sucralose
Number of subjects: 138

Group type: COMPARATOR
Intervention: Maqui-citrus beverage with sucrose
Number of subjects: 138
Study: 32833063

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33046145

Group type: EXPERIMENTAL
Intervention: Probands with ADHD
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 159

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 159
Study: 34488846

Group type: EXPERIMENTAL
Intervention: 40 mg/kg PZQ at baseline and placebo at 6 months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 40 mg/kg PZQ at baseline and 40 mg/kg PZQ at 6 months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 80 mg/kg PZQ at baseline and placebo at 6 months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 80 mg/kg PZQ at baseline and 80 mg/kg PZQ at 6 months
Number of subjects: 600
Study: 33369355

Group type: EXPERIMENTAL
Intervention: CC-486 (300 mg) once daily for 14 days per 28-day cycle
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo once daily for 14 days per 28-day cycle
Number of subjects: 472
Study: 35783319

Group type: EXPERIMENTAL
Intervention: Group-based parenting intervention
Number of subjects: 785

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 785
Study: 32000812

Group type: EXPERIMENTAL
Intervention: EHR-based intervention
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Phone coaching
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Continued EHR
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Continued TM
Number of subjects: 6000
Study: 35183780

Group type: EXPERIMENTAL
Intervention: 5 µm of Rose Bengal (RB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neem extract
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tea tree oil (TTO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.12% CHX solutions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 33761442

Group type: EXPERIMENTAL
Intervention: Health facilities (HFs) contacted by BMS company representatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health personnel knowledge of the WHO Code
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advice received by mothers on feeding their children BMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Points of sale (POS) compliance with the WHO Code
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS labels compliance with the WHO Code
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS advertising expenses in the media
Number of subjects: 0
Study: 35247444

Group type: EXPERIMENTAL
Intervention: 6.5%‐isomaltulose
Number of subjects: 13

Group type: COMPARATOR
Intervention: 6.5%‐sucrose
Number of subjects: 13

Group type: COMPARATOR
Intervention: water
Number of subjects: 13
Study: 34600585

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (C/T) 3g every 8 hours
Number of subjects: 459

Group type: COMPARATOR
Intervention: Meropenem 1g every 8 hours
Number of subjects: 459
Study: 32750572

Group type: EXPERIMENTAL
Intervention: Daily symptom check-in text messages, plus medication reminder or inspirational quote text
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 40
Study: 35795313

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 900 mg twice daily for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33721560

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks for 16 cycles or up to 1 year
Number of subjects: 809

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 809
Study: 35678894

Group type: EXPERIMENTAL
Intervention: CIU‐SP (intraureteral stent placement)
Number of subjects: 91
Study: 34622679

Group type: EXPERIMENTAL
Intervention: DAPT with cilostazol and clopidogrel or aspirin
Number of subjects: 547

Group type: COMPARATOR
Intervention: SAPT with clopidogrel or aspirin
Number of subjects: 547
Study: 32293706

Group type: EXPERIMENTAL
Intervention: Pitolisant hydrochloride (40 mg)
Number of subjects: 6
Study: 35501349

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 32745891

Group type: EXPERIMENTAL
Intervention: Oxytocin 20 IU
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oxytocin 40 IU
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oxytocin (both doses)
Number of subjects: 97
Study: 32945015

Group type: EXPERIMENTAL
Intervention: Toric contact lenses
Number of subjects: 34

Group type: COMPARATOR
Intervention: Spherical equivalent contact lenses
Number of subjects: 34
Study: 34653740

Group type: EXPERIMENTAL
Intervention: Real intermittent theta burst stimulation (iTBS) targeting the cerebellar vermis area VII-B, 100% active motor threshold, two sessions/day for five days (total = 6000 pulses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 60
Study: 33314397

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 37277072

Group type: EXPERIMENTAL
Intervention: Dexpramipexole 150 mg BID
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dexpramipexole 75 mg BID
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 34836388

Group type: EXPERIMENTAL
Intervention: Biobran/MGN-3 (500 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32635352

Group type: COMPARATOR
Intervention: Pedelec use (P)
Number of subjects: 101
Study: 35156616

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 0
Study: 33517607

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard oxygen treatment (venturi mask/nasal cannula)
Number of subjects: 100
Study: 32598165

Group type: EXPERIMENTAL
Intervention: Iowa Infant Feeding Attitudes Scale (IIFAS)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Baby Eating Behavior Questionnaire (BEBQ)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: General appetite score for Russian infants
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Satiety responsiveness score for Russian infants
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Agreement with IIFAS statement 'Formula feeding is more convenient than breastfeeding'
Number of subjects: 164
Study: 36288939

Group type: EXPERIMENTAL
Intervention: Ciclesonide 400 µg three times a day for seven days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 42
Study: 33085032

Group type: EXPERIMENTAL
Intervention: palbociclib plus letrozole
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo plus letrozole
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: palbociclib plus fulvestrant
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo plus fulvestrant
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: palbociclib
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 35791768

Group type: EXPERIMENTAL
Intervention: Postoperative SpO2 ≤ 94%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Postoperative FVC ≤ 50%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Preoperative SpO2
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Preoperative FVC
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Preoperative poorly aerated lung volume
Number of subjects: 45
Study: 32439849

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ingestion
Number of subjects: 0
Study: 35436957

Group type: EXPERIMENTAL
Intervention: Intensive education program on treatment of tobacco-use disorder
Number of subjects: 86

Group type: COMPARATOR
Intervention: Short didactic session on a non-tobacco-related topic (Control)
Number of subjects: 86
Study: 34385707

Group type: EXPERIMENTAL
Intervention: gosuranemab
Number of subjects: 486

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 486
Study: 33030598

Group type: EXPERIMENTAL
Intervention: Supervised aerobic endurance, resistance, and balance exercises twice a week at the hospital plus home-based exercise once a week for 12-24 weeks
Number of subjects: 30
Study: 34747972

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention promoting healthy diet and physical activity, engaging schools and families, with the assistance of a smartphone app.
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Control group engaged in usual practices.
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 1392
Study: 34047915

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Staged excision (SE)
Number of subjects: 31
Study: 32682770

Group type: EXPERIMENTAL
Intervention: Home mechanical ventilation (HMV) initiation
Number of subjects: 96

Group type: COMPARATOR
Intervention: In-hospital mechanical ventilation (HMV) initiation
Number of subjects: 96
Study: 36195326

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radiofrequency ablation (RFA)
Number of subjects: 1279
Study: 35768989

Group type: EXPERIMENTAL
Intervention: ESI with betamethasone (ESI‐beta)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: ESI with dexamethasone (ESI‐dexa)
Number of subjects: 600
Study: 33347003

Group type: EXPERIMENTAL
Intervention: VYC‐20L
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (6 months later)
Number of subjects: 192
Study: 34353046

Group type: EXPERIMENTAL
Intervention: ICU nursing risk management combined with the cluster nursing model
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 110
Study: 32362552

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 170

Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab (subgroup with BCVA ≤69 letters)
Number of subjects: 170

Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab (subgroup with BCVA ≤69 letters)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab (subgroup with BCVA ≥70 letters)
Number of subjects: 170

Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab (subgroup with BCVA ≥70 letters)
Number of subjects: 170
Study: 35797047

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 270
Study: 33506973

Group type: EXPERIMENTAL
Intervention: Health professional-led functional exercise programme (n = 78), performed up to four times a day, 7 days a week for 2 weeks, in addition to usual care.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care alone (n = 62).
Number of subjects: 140
Study: 32404854

Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy (LH)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Open hepatectomy (OH)
Number of subjects: 160
Study: 35700977

Group type: EXPERIMENTAL
Intervention: Adapted exercise and education curriculum (Fit & Strong!)
Number of subjects: 0
Study: 33668564

Group type: EXPERIMENTAL
Intervention: EGF-containing ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petrolatum (Control)
Number of subjects: 0
Study: 32594785

Group type: EXPERIMENTAL
Intervention: BAC-preserved timolol
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: BAC-preserved brimonidine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Preservative-free timolol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 85
Study: 36154487

Group type: EXPERIMENTAL
Intervention: Dramatic narrative featuring Latina characters countering prevalent myths about COVID-19 vaccines
Number of subjects: 390

Group type: COMPARATOR
Intervention: Nonnarrative control film containing similar information
Number of subjects: 390
Study: 32089450

Group type: EXPERIMENTAL
Intervention: cVEMP test
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: oVEMP test
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: caloric test
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: vHIT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SHIMP test
Number of subjects: 22
Study: 36301511

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (20 mg/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enteral caffeine (20 mg/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (5 mg/kg second dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enteral caffeine (5 mg/kg second dose)
Number of subjects: 38
Study: 35565828

Group type: EXPERIMENTAL
Intervention: Mg-Teadiola (combination of magnesium, vitamins B6, B9, B12, rhodiola, and green tea/L-theanine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mg-Teadiola
Number of subjects: 100
Study: 615916192

Group type: EXPERIMENTAL
Intervention: Monocular perimetry
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Binocular perimetry
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both monocular and binocular perimetry
Number of subjects: 11
Study: 35126882

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 33639003

Group type: EXPERIMENTAL
Intervention: Full Skin Examination (FSE)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Targeted Lesion Examination (TLE)
Number of subjects: 763
Study: 33136072

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional kinesiotherapy (CON)
Number of subjects: 47
Study: 34265578

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (5 sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 44
Study: 32143147

Group type: EXPERIMENTAL
Intervention: Functional binding immunoassay methods (specifically FXIIa-binding method)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional chromogenic assay
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Immunoassays based on functional binding to activated complement C1s or Factor XIIa/kallikrein
Number of subjects: 65
Study: 32022261

Group type: EXPERIMENTAL
Intervention: APG-157 (100 mg or 200 mg, delivered transorally every hour for 3 hours)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APG-157
Number of subjects: 25
Study: 35199968

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 33105387

Group type: EXPERIMENTAL
Intervention: LOW steps (2675 ± 314 steps per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LIMITED steps (4759 ± 276 steps per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NORMAL steps (8481 ± 581 steps per day)
Number of subjects: 10
Study: 33320035

Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 815
Study: 34896732

Group type: EXPERIMENTAL
Intervention: 3-hour diaper changes
Number of subjects: 46

Group type: COMPARATOR
Intervention: 6-hour diaper changes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diaper change during BCEs
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infants awake at the beginning of BCEs
Number of subjects: 46
Study: 34112734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Baseline blood eosinophil counts ≥300 cells·μL‐1 and FENO ≥50 ppb
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Persistent eosinophil and FENO elevations
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Combination of eosinophils and FENO
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (exacerbation history, corticosteroid use, nasal polyposis, Asian race, geographic region)
Number of subjects: 2016
Study: 33107924

Group type: EXPERIMENTAL
Intervention: Out-of-hospital tranexamic acid
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31